|The following article is part of conference coverage from the NKF 2018 Spring Clinical Meetings in Austin hosted by the National Kidney Foundation. Renal & Urology News staff will be reporting on medical studies conducted by nephrologists and other specialists who are tops in their field in chronic kidney disease, dialysis, transplantation, and more. Check back for the latest news from NKF 2018.|
AUSTIN, Texas—Thrice-weekly administration of cinacalcet after in-center hemodialysis (HD) sessions is a safe and effective alternative to daily oral administration, researchers concluded in a poster presentation at the National Kidney Foundation’s 2018 Spring Clinical Meetings.
In a pilot study of 10 patients (mean age 56 years; 36% female; 64% black) with baseline parathyroid hormone (PTH) levels of 150 to 1000 pg/mL, control of PTH did not differ markedly at 48 and 72 hours after in-center HD compared with 24 hours after daily oral administration of 30 mg cinacalcet. In addition, the pharmacokinetics for post-dialysis cinacalcet were in line with published literature, Jeffrey Connaire, MD, of DaVita Clinical Research in Minneapolis, and colleagues reported.
Severe hypocalcemia did not develop any patient following post-HD cinacalcet administration. Vital signs and electrocardiography results were normal. Three participants reported minor adverse events, including emesis, nausea, diarrhea, and myalgia.
See more coverage from the National Kidney Foundation Spring Clinical meeting
Connaire J, Brunelli S, Aronoff G, et al. Pharmacokinetics (PK), safety, and tolerability of thrice-weekly dosing of cinacalcet in hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT). Poster presented at the National Kidney Foundation’s 2018 Spring Clinical Meetings in Austin, Texas, April 10-14, 2018. Poster 363.